New York State Common Retirement Fund Sells 6,573 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,725 shares of the medical research company's stock after selling 6,573 shares during the period. New York State Common Retirement Fund owned 0.23% of Charles River Laboratories International worth $23,582,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CRL. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares during the period. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International in the third quarter valued at approximately $32,000. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth approximately $41,000. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock worth $58,000 after purchasing an additional 193 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Charles River Laboratories International in the third quarter valued at $79,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $1.52 on Monday, hitting $182.48. 518,897 shares of the stock were exchanged, compared to its average volume of 605,207. The firm has a market capitalization of $9.42 billion, a PE ratio of 21.85, a P/E/G ratio of 6.12 and a beta of 1.38. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $193.72 and its two-hundred day moving average is $209.14. Charles River Laboratories International, Inc. has a one year low of $166.87 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has initiated a share buyback plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Redburn Atlantic started coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price target on the stock. Robert W. Baird decreased their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a report on Friday, September 20th. Bank of America downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. Evercore ISI downgraded Charles River Laboratories International from an "outperform" rating to an "inline" rating and lowered their price objective for the stock from $225.00 to $190.00 in a research report on Monday, October 7th. Finally, UBS Group reduced their target price on Charles River Laboratories International from $290.00 to $240.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $209.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).